Ultragenyx Gene Therapy for Sanfilippo Syndrome Nears FDA Decision

Event summary

  • Ultragenyx received FDA acceptance for a resubmitted Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome Type A.
  • The FDA has set a PDUFA action date of September 19, 2026, for the review.
  • UX111 would be the first approved therapy for Sanfilippo syndrome Type A, a rare, fatal neurodegenerative disorder.
  • Long-term clinical data, spanning up to 8 years, were included in the resubmission and presented at WORLDSymposium™ 2026.

The big picture

The acceptance of UX111’s BLA represents a significant milestone in the development of gene therapies for rare neurological disorders, a market increasingly attracting investment. While the therapy addresses a small patient population (estimated 3,000-5,000 globally), the lack of existing treatments commands a premium price, potentially generating substantial revenue if approved. The FDA’s decision will serve as a key indicator for the broader AAV gene therapy field, particularly for companies targeting other rare genetic diseases.

What we're watching

Regulatory Risk
The FDA’s review hinges on the acceptance of long-term data; a rejection or request for additional studies could significantly delay approval and impact Ultragenyx’s valuation.
Manufacturing Scale
Successful commercialization depends on Ultragenyx’s ability to scale manufacturing at both Andelyn Biosciences and its own facility; production bottlenecks could limit supply and revenue potential.
Market Adoption
Given the disease's rarity and the therapy's high price point, market adoption will be heavily influenced by reimbursement policies and patient access programs, which could impact revenue projections.